BEACONs: A novel nanoparticle adjuvant approach for mucosal vaccination against genital herpes
By
Akiko Iwasaki
Summary
This article presents research on a novel adjuvant called BEACONs (Bioactive Enhanced Adjuvant Chemokine Oligonucleotide Nanoparticles) developed for mucosal vaccination against genital herpes (HSV-2). The BEACONs combine CpG oligodeoxynucleotides with the CXCL9 chemokine through electrostatic interactions. The study describes a vaccination strategy where mice were primed with intramuscular injections of mRNA lipid nanoparticles encoding HSV-2 glycoproteins (gB or gD) and then boosted intra... The research addresses the challenge of triggering localized immune responses in the reproductive tract mucosa, which has been a key obstacle in developing an effective HSV-2 vaccine.
Source
Twitter / XBEACONs: A novel nanoparticle adjuvant approach for mucosal vaccination against genital herpesscim.agKey quotes
· 3 pulledNo vaccine currently exists for genital herpes, caused by herpes simplex virus 2 (HSV-2), in part because of the challenge of triggering localized immune responses in the reproductive tract mucosa.
Bhagchandani et al. generated an adjuvant called bioactive enhanced adjuvant chemokine oligonucleotide nanoparticles (BEACONs) that combines CpG oligodeoxynucleotides (CpG ODNs) with the CXCL9 chemokine through electrostatic interactions.
Mice were primed initially by intramuscular injection with mRNA lipid nanoparticles encoding HSV-2 glycoprotein B (gB) or gD and were boosted intra...
You might also wanna read
mRNA-LNP Platforms Show Promise for Inducing Immune Tolerance in Peanut Allergy Treatment
This article discusses the development of mRNA-lipid nanoparticle (LNP) platforms designed to induce antigen-specific immune tolerance for p
pubs.acs.org·16d ago
Personalized mRNA vaccine shows promise in preventing melanoma recurrence when combined with immunotherapy
An 80-year-old melanoma patient, Connie Franciosi, participated in a clinical trial testing an mRNA cancer vaccine (mRNA-4157/V940) combined
share.google·22d ago
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·5mo ago
Personalized mRNA vaccine combined with Keytruda shows 49% reduction in melanoma recurrence risk
An 80-year-old melanoma patient, Connie Franciosi, participated in a clinical trial testing an mRNA cancer vaccine (mRNA-4157/V940) combined
npr.org·6d agoPersonalized mRNA vaccine combined with Keytruda shows 49% reduction in melanoma recurrence risk
An 80-year-old melanoma patient, Connie Franciosi, participated in a clinical trial testing an mRNA cancer vaccine (mRNA-4157/V940) combined
npr.org·6d ago
Pneumococcal membrane particles show promise for serotype-independent vaccine protection against Streptococcus pneumoniae colonization
This scientific research article presents a study on pneumococcal membrane particles as a potential vaccine strategy against Streptococcus p
pnas.org·28d ago
Flagellin in biotechnology: biosensors, nanomaterials, and nanorobots beyond bacterial motility
This review article discusses recent advances in using flagellin (the bacterial flagellar filament protein) for biotechnology applications b
Comments
Sign in to join the conversation.
No comments yet. Be the first.